Publication: 159

Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients with Unresectable Stage IV Melanoma – A North Central Cancer Treatment Group (NCCTG) Study, N047A1
      QxMD      Google Scholar   
Citation:
Cancer vol 115 (1) 119-127
Year:
2009
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
652  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA035267, M01 RR000585, U10 CA052352, N01 CA035431, U10 CA035269, M01 RR000585-332026, CA-35090, U10 CA060276, CA-52352, CA-35195, M01 RR000585-332075, U10 CA035195, CA-35103, CA-25224, CA-60276, U10 CA035101, U10 CA063849, M01 RR000585-342075, U10 CA035431, CA-35269, CA-35101, U10 CA025224, U10 CA035090, CA-35267, CA-63849, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-N047A
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Metastatic melanoma, angiogenesis, chemotherapy, phase II trials